Edgewise Therapeutics, Inc. Common Stock
Here’s whether Edgewise Therapeutics, Inc. Common Stock (EWTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.27% over 10 days); RSI 57 — healthy momentum range; strong 1-year return of +140.2%; 3-month momentum positive (+24.2%); rising volume confirms the move (1.18x 30d avg). Currently 12.7% off its 52-week high. Score: +8/7.
EWTX is in a confirmed uptrend, trading above both its 50-day ($33.36) and 200-day ($25.09) moving averages. An RSI of 57.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +140.2% compares to +24.4% for SPY (beat the market by 115.8%).